JavaScript seem to be disabled in your browser.
You must have JavaScript enabled in your browser to utilize the functionality of this website.
Human Interleukin-18 is a proinflammatory cytokine in the IL-1 family that exerts distinct immune effects depending on the local cytokine environment. It is expressed as a 24 kDa precursor by endothelial and epithelial cells, keratinocytes, gamma δ T cells, and phagocytes. The precursor is activated intracellularly by Caspase-1 mediated proteolysis to release the 17 kDa mature cytokine. The precursor can also be released by necrotic cells for extracellular cleavage by multiple proteases. IL-18 activation is induced by infection or tissue damage and contributes to disease pathology in chronic inflammation. IL-18 binds to the widely expressedIL-18 R alpha which recruits IL-18 R beta to form the signaling receptor complex. Its bioactivity is negatively regulated by interactions with IL-18 binding proteins and virally encoded IL-18BP homologs.
The manufacturing and testing of Recombinant Human Interleukin-18 GMP complies with ICH Q7 guidelines.
> 95% by SDS-PAGE> 98% by HPLC
ED50 = 1.5-15 ng/ml, determined by the ability to induce IFN-gamma secretion by KG-1 human acute myelogenous leukemia cells
> 3.0 x 106 Units/mg, calibrated against the rhIL-18 WHO reference standard (NIBSC code: 03/200)